- $1.43bn
- $1.47bn
- $1.30m
Inhibrx Biosciences Q4 net loss narrows as expenses fall
Brief: Inhibrx Biosciences, Inc Provides Progress Updates On The Inbrx-106 Program And The Expansion Cohorts Of The Ozekibart (Inbrx-109) Program
Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates
Brief: Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts
Inhibrx shares surge after bone cancer drug slows disease progression in trial
Brief: Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Inhibrx Biosciences Inc expected to post a loss of $2.76 a share - Earnings Preview
Brief: Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President
Brief: Inhibrx Biosciences Announces Loan Agreement With Oxford Finance
Brief: Inhibrx Biosciences Inc Legal Victory In A Trade Secrets Case Brought By I-Mab Biopharma
U.S. RESEARCH ROUNDUP-Applied Materials, Lam Research, S&P Global
Brief: Inhibrx Biosciences Reports Second Quarter 2024 Financial Results
Brief: Viking Global Investors Lp Reports 12.3% Passive Stake In Inhibrx Biosciences, Inc. As Of May 29, 2024- SEC Filing